TW200616679A - Modified-release preparation - Google Patents

Modified-release preparation

Info

Publication number
TW200616679A
TW200616679A TW094133910A TW94133910A TW200616679A TW 200616679 A TW200616679 A TW 200616679A TW 094133910 A TW094133910 A TW 094133910A TW 94133910 A TW94133910 A TW 94133910A TW 200616679 A TW200616679 A TW 200616679A
Authority
TW
Taiwan
Prior art keywords
substituted
compound
ring
bond
group
Prior art date
Application number
TW094133910A
Other languages
Chinese (zh)
Inventor
Akihiko Ono
Shuji Yoneyama
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of TW200616679A publication Critical patent/TW200616679A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

The present invention relates to a pharmaceutical agent comprising a combination of two or more parts comprising a compound of the formula: , wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X represents a bond, or the like; m represents an integer of 0 to 3; Y represents an oxygen atom or the like; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group; X1 represents a bond or the like; R2 represents a hydrogen atom or the like; W represents a bond or the like; R3 represents a group of the formula: -OR8 (R8 represents a hydrogen atom or a hydrocarbon group which may be substituted) or the like; or a salt thereof, said two or more parts have mutually different release rates of the compound or a salt thereof. According to the present invention, a pharmaceutical agent comprising a nitrogen containing 5-membered heterocyclic compound useful as an agent for the prophylaxis or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance, inflammatory diseases, arteriosclerosis and the like, which has improved sustainability of an effective blood concentration of the compound, can be provided.
TW094133910A 2004-09-30 2005-09-29 Modified-release preparation TW200616679A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004287244 2004-09-30

Publications (1)

Publication Number Publication Date
TW200616679A true TW200616679A (en) 2006-06-01

Family

ID=36119292

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094133910A TW200616679A (en) 2004-09-30 2005-09-29 Modified-release preparation

Country Status (2)

Country Link
TW (1) TW200616679A (en)
WO (1) WO2006036007A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5366558B2 (en) * 2006-12-28 2013-12-11 武田薬品工業株式会社 Orally disintegrating solid preparation
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
JP5827952B2 (en) 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． Pharmaceutical composition having both rapid action and durability
MX350056B (en) 2009-11-03 2017-08-25 Lupin Ltd Modified release formulation of lacosamide.
WO2011101863A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
JP6902033B2 (en) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド Methods and compositions for the treatment of seizure-related disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179823B1 (en) * 1999-11-10 2007-02-20 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US7368578B2 (en) * 2002-09-10 2008-05-06 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds

Also Published As

Publication number Publication date
WO2006036007A2 (en) 2006-04-06
WO2006036007A3 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
MY142807A (en) Benzimidazole derivative and use thereof.
MD20110063A2 (en) Herbicidal compositions containing benzoylpyrazole compounds
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
MX2009010024A (en) Novel adenine compound.
EP1775289A4 (en) Novel imidazolidine derivatives
TW200637869A (en) The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
WO2005097129A3 (en) 6-azaindole compound
EA200601830A1 (en) ORT-SUBSTITUTED ARYL OR HETEROARYL AMIDAL COMPOUNDS
TW200745034A (en) New compounds
MY153045A (en) Oxopyrazine derivative and herbicide
UA95255C2 (en) Azole and thiazole derivatives and their use
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
EP1679309A4 (en) Antistress drug and medical use thereof
WO2004037181A3 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
TW200505919A (en) DPP-IV inhibitors
MY148566A (en) Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
CA2428271A1 (en) Cyanopyrrolidine derivatives as inhibitors of dpp-iv
TNSN07397A1 (en) Acetylene derivatives
GB0129476D0 (en) Organic compounds
DK1961734T3 (en) Amine compound and its use for medical purposes
DE602008001725D1 (en) 1- (1-BENZYLPIPERIDIN-4-YL) BENZIMIDAZOLE-5-CARBOXYLENE DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS
GEP20125637B (en) Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
MX2010001566A (en) Aminopyrazole amide derivative.
WO2008126901A1 (en) Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
TW200616679A (en) Modified-release preparation